Bridging the Consumer‐Medical Divide

While 23andMe aspires to be “the world's trusted source of personal genetic information,” the U.S. Food and Drug Administration (FDA) believes that the company's advertising practices have been anything but trustworthy. Last November, a harshly worded FDA “warning letter” demanded that the direct‐to‐consumer genetic testing company immediately discontinue marketing its unapproved “medical device.” The tussle between 23andMe and the FDA has attracted more attention than a typical disagreement between a company and a government agency. Larry Downes and Paul Nunes identify 23andMe as a “Big Bang Disruption”: an invention that revolutionizes the existing market, foiling both industry incumbents and unprepared regulators. The outcome of the FDA's current review to hold the answer to the million‐dollar question: how will DTC genetic testing be regulated in the future? Ideally, the FDA's regulations should not pose undue burdens on consumers seeking personal genetic information but, rather, help consumers make a transition out of the consumer setting and into the medical setting

Advertising · Agency (philosophy) · Business · Consumer Advocacy · Consumer education · Consumer safety · Direct-to-consumer advertising · Food and drug administration · Genetic testing · Government (linguistics) · Government regulation · Internet privacy · Liberian dollar · Political science · Public relations · Sociology · Trustworthiness · Biomedical Ethics and Regulation · Computer Science · Finance · Intellectual Property and Patents · Law · Legal Systems and Judicial Processes · Marketing · Medicine · Pharmacology

• Multi-stakeholder involvement in urban land use planning in the Ejisu Municipality, Ghana

  Open Access•Michael Poku‐boansi, Michael Poku-Boansi•Land Use Policy•2021

  Add to list

• Regulatory controls for direct-to-consumer genetic tests

  Open Access•Margaret Curnutte•New Genetics and Society•2017

  Add to list